Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B

Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates, conversion rates, and fractional catabolic rates (FCR)....

Full description

Bibliographic Details
Main Authors: Klaus G. Parhofer, P. Hugh R. Barrett, Thomas Demant, Peter Schwandt
Format: Article
Language:English
Published: Elsevier 2000-10-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520319921
id doaj-e967d0ad94f54a31883d89cb1231c662
record_format Article
spelling doaj-e967d0ad94f54a31883d89cb1231c6622021-04-27T04:41:36ZengElsevierJournal of Lipid Research0022-22752000-10-01411015961603Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein BKlaus G. Parhofer0P. Hugh R. Barrett1Thomas Demant2Peter Schwandt3To whom correspondence should be addressed.; Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Clinical Chemistry, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Medicine, University of Western Australia, Perth, Western Australia, Australia 6000Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Clinical Chemistry, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Medicine, University of Western Australia, Perth, Western Australia, Australia 6000Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Clinical Chemistry, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Medicine, University of Western Australia, Perth, Western Australia, Australia 6000Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Clinical Chemistry, Klinikum Grosshadern, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; Department of Medicine, University of Western Australia, Perth, Western Australia, Australia 6000Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates, conversion rates, and fractional catabolic rates (FCR). We studied the acute effect of apheresis on metabolic parameters of apoB in five patients with drug-resistant hyperlipoproteinemia, using endogenous labeling with D3-leucine, mass spectrometry, and multicompartmental modeling. Patients were studied prior to and immediately after apheresis therapy. The two tracer studies were modeled simultaneously, taking into account the non-steady-state concentrations of apoB. The low density lipoprotein (LDL)-apoB concentration was 120 ± 32 mg dl−1 prior to and 52 ± 18 mg dl−1 immediately after apheresis therapy. The metabolic studies indicate that no change in apoB secretion (13.9 ± 4.9 mg kg−1 day−1) is required to fit the tracer and apoB mass data obtained before and after apheresis and that in four of the five patients the LDL-apoB FCR (0.21 ± 0.02 day−1) was not altered after apheresis. In one subject the LDL-apoB FCR temporarily increased from 0.22 day−1 to 0.35 day−1 after apheresis. The conversion rate of very low density lipoprotein (VLDL)-apoB to LDL-apoB is temporarily decreased from 76 to 51% after apheresis and thus less LDL-apoB is produced after apheresis. We conclude that an acute reduction of LDL-apoB concentration does not affect apoB secretion or LDL-apoB FCR, but that apoB conversion to LDL is temporarily decreased. Thus, in most patients the decreased rate of delivery of neutral lipids or apoB to the liver does not result in an upregulation of LDL receptors or in decreased apoB secretion.—Parhofer, K. G., P. H. R. Barrett, T. Demant, and P. Schwandt. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J. Lipid Res. 2000. 41: 1596–1603.http://www.sciencedirect.com/science/article/pii/S0022227520319921apheresislipoprotein metabolismapoB-100non-steady-state kineticskineticscompartmental models
collection DOAJ
language English
format Article
sources DOAJ
author Klaus G. Parhofer
P. Hugh R. Barrett
Thomas Demant
Peter Schwandt
spellingShingle Klaus G. Parhofer
P. Hugh R. Barrett
Thomas Demant
Peter Schwandt
Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
Journal of Lipid Research
apheresis
lipoprotein metabolism
apoB-100
non-steady-state kinetics
kinetics
compartmental models
author_facet Klaus G. Parhofer
P. Hugh R. Barrett
Thomas Demant
Peter Schwandt
author_sort Klaus G. Parhofer
title Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
title_short Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
title_full Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
title_fullStr Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
title_full_unstemmed Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
title_sort acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein b
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2000-10-01
description Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates, conversion rates, and fractional catabolic rates (FCR). We studied the acute effect of apheresis on metabolic parameters of apoB in five patients with drug-resistant hyperlipoproteinemia, using endogenous labeling with D3-leucine, mass spectrometry, and multicompartmental modeling. Patients were studied prior to and immediately after apheresis therapy. The two tracer studies were modeled simultaneously, taking into account the non-steady-state concentrations of apoB. The low density lipoprotein (LDL)-apoB concentration was 120 ± 32 mg dl−1 prior to and 52 ± 18 mg dl−1 immediately after apheresis therapy. The metabolic studies indicate that no change in apoB secretion (13.9 ± 4.9 mg kg−1 day−1) is required to fit the tracer and apoB mass data obtained before and after apheresis and that in four of the five patients the LDL-apoB FCR (0.21 ± 0.02 day−1) was not altered after apheresis. In one subject the LDL-apoB FCR temporarily increased from 0.22 day−1 to 0.35 day−1 after apheresis. The conversion rate of very low density lipoprotein (VLDL)-apoB to LDL-apoB is temporarily decreased from 76 to 51% after apheresis and thus less LDL-apoB is produced after apheresis. We conclude that an acute reduction of LDL-apoB concentration does not affect apoB secretion or LDL-apoB FCR, but that apoB conversion to LDL is temporarily decreased. Thus, in most patients the decreased rate of delivery of neutral lipids or apoB to the liver does not result in an upregulation of LDL receptors or in decreased apoB secretion.—Parhofer, K. G., P. H. R. Barrett, T. Demant, and P. Schwandt. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J. Lipid Res. 2000. 41: 1596–1603.
topic apheresis
lipoprotein metabolism
apoB-100
non-steady-state kinetics
kinetics
compartmental models
url http://www.sciencedirect.com/science/article/pii/S0022227520319921
work_keys_str_mv AT klausgparhofer acuteeffectsoflowdensitylipoproteinapheresisonmetabolicparametersofapolipoproteinb
AT phughrbarrett acuteeffectsoflowdensitylipoproteinapheresisonmetabolicparametersofapolipoproteinb
AT thomasdemant acuteeffectsoflowdensitylipoproteinapheresisonmetabolicparametersofapolipoproteinb
AT peterschwandt acuteeffectsoflowdensitylipoproteinapheresisonmetabolicparametersofapolipoproteinb
_version_ 1721506853811126272